Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly (LLY) reported fourth quarter and full-year earnings for 2024 on Thursday. The results largely beat Wall Street estimates and sent the stock up about 2%. But the company missed on GLP-1 ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly (NYSE:LLY) reported strong Q4 2024 ... Sales of GLP1 therapy tirzepatide marketed as Mounjaro for diabetes and Zepbound for weight loss reached $5.4 billion reflecting 128% year-over ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Eli Lilly expects 2024 revenue to be $45 billion, with Mounjaro and Zepbound sales contributing ... In October 2024, the FDA determined that Eli Lilly’s tirzepatide injection shortage had ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...